These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37114510)

  • 1. Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer.
    Kumar S; Sengupta S; Ali I; Gupta MK; Lalhlenmawia H; Azizov S; Kumar D
    J Biomol Struct Dyn; 2023; 41(21):11353-11372. PubMed ID: 37114510
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kumar S; Ali I; Abbas F; Rana A; Pandey S; Garg M; Kumar D
    J Biomol Struct Dyn; 2024 Nov; 42(18):9416-9438. PubMed ID: 37646177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
    Muthuvel SK; Elumalai E; K G; K H
    J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico target specific design of potential quinazoline-based anti-NSCLC agents.
    Mohammadnejadi E; Razzaghi-Asl N
    J Biomol Struct Dyn; 2023 Dec; 41(20):10725-10736. PubMed ID: 36826424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
    Kumar S; Ali I; Abbas F; Khan N; Gupta MK; Garg M; Kumar S; Kumar D
    In Silico Pharmacol; 2023; 11(1):20. PubMed ID: 37575679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-silico identification and exploration of small molecule coumarin-1,2,3-triazole hybrids as potential EGFR inhibitors for targeting lung cancer.
    Kumar S; Ali I; Abbas F; Shafiq F; Yadav AK; Ghate MD; Kumar D
    Mol Divers; 2024 Dec; 28(6):4301-4324. PubMed ID: 38470555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A series of quinazolin-4(3H)-one-morpholine hybrids as anti-lung-cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies.
    Tokalı FS; Şenol H; Ateşoğlu Ş; Akbaş F
    Chem Biol Drug Des; 2024 Jul; 104(1):e14599. PubMed ID: 39039616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-EGFR potential of quinazoline derivatives using molecular docking: An in silico approach.
    Tanveer F; Anwar MF; Siraj B; Zarina S
    Biotechnol Appl Biochem; 2022 Jun; 69(3):1226-1237. PubMed ID: 34028091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
    Reddy PS; Lokhande KB; Nagar S; Reddy VD; Murthy PS; Swamy KV
    Curr Comput Aided Drug Des; 2018; 14(3):246-252. PubMed ID: 29493460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858R/T790M/C797S Mutant EGFR Inhibitors.
    Bhandari SV; Kuthe PV; Patil SM; Nagras OG; Sarkate AP; Chaudhari SY; Surve SV
    Chem Biodivers; 2023 Nov; 20(11):e202301081. PubMed ID: 37793119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics.
    Ahmad Ansari I; Debnath B; Kar S; Patel HM; Debnath S; Zaki MEA; Pal P
    J Biomol Struct Dyn; 2024 Mar; 42(5):2464-2481. PubMed ID: 37349948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
    Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
    J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided anti-cancer drug discovery of EGFR protein based on virtual screening of drug bank, ADMET, docking, DFT and molecular dynamic simulation studies.
    Roney M; Dubey A; Hassan Nasir M; Tufail A; Tajuddin SN; Mohd Aluwi MFF; Huq AM
    J Biomol Struct Dyn; 2024 Nov; 42(18):9662-9677. PubMed ID: 37676262
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Imana SN; Ningsih EG; Tambunan USF
    Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
    Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
    Molecules; 2021 May; 26(10):. PubMed ID: 34069962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
    Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
    Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
    Saini N; Grewal AS; Lather V; Gahlawat SK
    Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.